EMA Reflects on Coated Nanomedicines - - BioPharm International

ADVERTISEMENT

EMA Reflects on Coated Nanomedicines


The European Medicines Agency (EMA) has published a reflection paper on general issues regarding the development of coated nanomedicines. The paper addresses issues that may arise in the development of nanomedicines that have a coating, including the effect of the coating on stability and possible interactions with other molecules.

The reflection paper is one in a series of four guidance documents discussing nanomedicines. EMA’s Committee for Medicinal Products for Human Use began developing guidance on the development of new nanomedicines and nanosimilars in 2011.

Source: European Medicines Agency

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines

Click here